Open an account

MoonLake Immunotherapeutics

MLTX · NASDAQ

$10.32+$0.57 (+5.85%)TodayMarket closed ·
Prev close $9.75

About MLTX

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 130 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Employees
130
Headquarters
Zug, Zug
Listed
Oct 20, 2020
Sector
Health Care
Industry
Biotechnology
Website
moonlaketx.com

MLTX key statistics

Market cap
878.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.85M
Volume
1.24M
Open price
$9.77
High today
$10.48
Low today
$9.73
52 Week high
$23.29
52 Week low
$8.90

MoonLake Immunotherapeutics (MLTX) at a glance

MoonLake Immunotherapeutics (MLTX) last traded at $10.32, with a market cap of 878.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.73 and $10.48. The current price is 6.1% above the day's low and 1.5% below its high.

Volume so far is 1.24M shares, below the average of 1.85M shares a day.

Over the past year MoonLake Immunotherapeutics has ranged from $8.90 to $23.29, and now sits 10% of the way up that range.

The average analyst price target is $32.13, 211.3% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

73%of 11 analyst ratings say Buy
  • Buy72.7%
  • Hold9.1%
  • Sell18.2%
Price target · 16 analystsAvg $32.13
Low
$6.06
Now
$10.32
High
$73.50

MLTX news

  • Vandana Singh

    MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

  • Vandana Singh

    Why Is MoonLake Immunotherapeutics Stock Soaring Monday?

  • Vandana Singh

    FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars

  • Vandana Singh

    Insmed Drug Misses Primary Goal, Program Axed

  • Vandana Singh

    MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing

  • Vandana Singh

    MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain

  • Vandana Singh

    Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

  • 10 Health Care Stocks Whale Activity In Today's Session

Similar companies

Companies in the same industry as MoonLake Immunotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.